STUDIES.
SCIENTIFIC RESEARCH
IN FOCUS.
NOA-09/CeTeG-Trial (randomized phase 3 study of combined CCNU/temozolomide therapy versus standard temozolomide therapy in first-line therapy of patients with newly diagnosed MGMT-methylated glioblastoma)
NOA-09/CeTeG-Trial (randomized phase 3 study of combined CCNU/temozolomide therapy versus standard temozolomide therapy in first-line therapy of patients with newly diagnosed MGMT-methylated glioblastoma)
The BMBF-funded CeTeG study is investigating whether combined CCNU/TMZ therapy in addition to standard radiotherapy is superior to standard TMZ therapy (Stupp regimen) in terms of overall survival. Only patients in whom a methylated MGMT promoter could be detected in the tumor were included. From 2011 to 2014, 141 patients were included in 17 German centers (1:1 randomization).